Australian Patent Office has accepted BioKier patent application number 2012250877 and a notice of the acceptance will appear in the Supplement to the Australian Official Journal of Patents on 21 July 2016. The present invention relates to a method of treating obesity, diabetes and other metabolic diseases by fixed combination of BioKier’s product with DPP IV inhibitors like vildagliptin. The patent will issue on October 21, 2016. Expiry for this patent is  May 2nd, 2032.